RxDoctor Payments Data

Anne Spencer, MD

Family Medicine · Austin, TXNPI 1699927111

Payments from drug & device makers

$4,363in general payments, 2019–2025

Across 242 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$546
  • AbbVie$497
  • Lilly USA, LLC$477
  • AstraZeneca$362
  • Pfizer$292
  • Amgen$291
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,363 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$140,086
Medicare patients
405
Services billed
3,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$108,495
JardianceEmpagliflozin53$69,269
FarxigaDapagliflozin Propanediol44$43,749
EliquisApixaban36$27,375
JanuviaSitagliptin Phosphate26$26,743
XareltoRivaroxaban23$24,351
Tresiba Flextouch U-200Insulin Degludec17$20,844
TrulicityDulaglutide17$18,934
MyrbetriqMirabegron19$14,628
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$13,599
MounjaroTirzepatide15$13,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$12,561
Repatha SureclickEvolocumab16$8,888
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,169
Breo ElliptaFluticasone/Vilanterol14$7,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$546$108,49585 claims
Boehringer IngelheimJardiance$241$69,26953 claims
AstraZenecaFarxiga, Breztri Aerosphere$362$51,91857 claims
Lilly USA, LLCTrulicity, Mounjaro$477$32,13632 claims
PfizerEliquis$292$27,37536 claims
MerckJanuvia$11$26,74326 claims
Johnson & JohnsonXarelto$11$24,35123 claims
GSKTrelegy Ellipta, Breo Ellipta$168$20,50532 claims
Astellas Pharma US IncMyrbetriq$106$14,62819 claims
AbbVieSynthroid$497$7,69688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →